Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID

Axcella Therapeutics is reducing its workforce by 85% as it drops its nonalcoholic fatty liver disease program and focuses its remaining resources on pushing the candidate as a long COVID treatment.